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Hodgkin’slymphoma(HL)occurswithincreasingfrequencyinhuman-immunodeﬁciency-virus-(HIV-)infectedindividuals.The
natural history and behaviour of HIV-HL is diﬀerent, being more atypical and aggressive. The association between HIV and HL
appears to be primarily EBV driven. HAART use does not signiﬁcantly impact on the incidence of HL. Indeed, the risk of HL
has increased in the post-HAART era. However, the advent of HAART has brought renewed hope, allowing standard therapeutic
optionstobeusedmoreoptimally, withbetter treatment outcomes. Despitethe renewed optimism,theoverall survivalofHIV-HL
patientsremainslessfavourablethanthatinHIV-seronegativepatients.Thisisparticularlytrueinsub-SaharanAfrica,wherethere
is a signiﬁcant burden of HIV/AIDS and where more than half the patients are HAART naive at diagnosis of HL. The similarities
and diﬀerences of a South African cohort of HIV-HL are presented in this paper.
1.Introduction
Human immunodeﬁciency virus (HIV) infection is known
to be associated with an increased risk of Hodgkin’s lym-
phoma (HL), based on linkage and cohort studies. The rela-
tive risk is now approximately 10-fold higher compared with
the general population [1–5]. Earlier studies suggest that
the HIV risk diﬀered between the European and American
cohorts with intravenous drug use being predominant in
the Italian and Spanish patients compared to the American,
where it was noted mainly in homosexual men [1, 2, 5, 6].
In sub-Saharan Africa, the major risk of acquiring HIV
occurs with heterosexual relationships. This is true for all the
patients in the series presented here (unpublished personal
data; see Table 1).
HL occurring in the setting of immunodeﬁciency is
generallyaggressive,characterizedbyadvanced-stagedisease,
frequent constitutional symptoms, less favourable histology,
more frequent bone marrow involvement, and a poorer
prognosis compared to immunocompetent individuals.
With the advent of HAART in 1996, the AIDS-
related morbidity, particularly with respect to opportunistic
infections, has decreased and the survival of HIV/AIDS
patients has increased. HAART has allowed the use of
standard therapeutic options to be delivered to seropositive
patients in a more optimal manner, bringing about renewed
optimism in the management of such patients. HAART use
is associated with higher CD4 T-cell counts and enhanced
immunity. Carbone et al. in 2009 [5] suggest that the
improved CD4 T-cell count that occurs after HAART
use provides antiapoptotic pathways and mechanisms for
immune escape by tumour cells, thus resulting in an
increased risk of HL [5].
A 20-year cohort study has shown that with the advent
of antiretroviral therapy, ADCs (AIDS-deﬁning cancers)
continue to fall, but the rates of NADCs (non-AIDS deﬁning
cancers) are on the increase. The authors conclude that this
increase appears to be more related to the aging of the HIV
population rather than the antiretroviral therapy and its
eﬀect on the CD4 T-cell count [7].
This paper will focus on the epidemiology, pathogenesis,
clinicalpresentation,andmanagementofHLinthesettingof
HIV.ThesimilaritiesanddiﬀerencesasobservedinSouthern
African patients will also be highlighted.2 Advances in Hematology
2. Epidemiology
With the advent of antiretroviral therapy, ADCs (AIDS-
deﬁning cancers) continue to fall, but the rates of NADCs
(non-AIDS deﬁning cancers) such as HL, anal carcinoma,
lung carcinoma, and skin cancers are on the increase
[7]. With HL, there is a noticeably increasing relative
risk of approximately 10-fold, compared with the general
population [1–6].
The epidemiology of HIV-HL is comprehensively
reviewed by Carbone et al. in 2009 [5]. In this excellent
review, the authors summarise the ﬁndings of several
epidemiological studies conducted in the last two decades,
which strongly support the evidence that HIV-positive
individuals have a higher risk of developing HL compared
to their HIV-negative counterparts. This is in contrast to
HIV-NHL or HIV-Kaposi’s sarcoma (where the incidence of
the disease has decreased signiﬁcantly after the introduction
of HAART). Thus, despite the beneﬁt of HAART, which
improves immunity and decreases the risk of opportunis-
tic infections, there is a paradoxically increased risk of
HL [5].
More than two thirds of all people with HIV live in sub-
Saharan Africa, and South Africa is home to the world’s
largest population of people living with HIV—5.7 million in
2007 [8]. Early studies in the mid 1990’s and early 2000’s
in South Africa (including patients from the Chris Hani
Baragwanath Hospital (CHBH)—a tertiary, public sector
hospital, linked to the University of the Witwatersrand,
and located in Soweto, Johannesburg) showed only a
modest increase of Non-Hodgkin’s Lymphoma (NHL) in
seropositive individuals, with odds ratios of 4.8, 5, and 5.9,
respectively [9–11].
However, at CHBH, since 2002, there has been a clearly
noticeable increase in the proportion of seropositive patients
with NHL (i.e., 60–70% of newly diagnosed patients with
NHL are HIV positive), and furthermore, there has been
a signiﬁcant increase in the total number of patients with
NHL since 2002 (from 20–30 new patients per year to 70–80
patients per year) [12]. Indeed, NHL is now the commonest
haematological malignancy in South Africa, in the current
HIV/AIDS era.
With respect to Hodgkin’s lymphoma (HL), the data is
less dramatic but is becoming more signiﬁcant. In a study by
Stein et al. in 2008 [11], the percentage of seropositivity of
HL in a South African cohort (which included patients from
CHBH) was 19.5% (OR = 1.6, 95%CI = 1.0–2.7), during the
period from 1995 to 2004. However, in the last 4 years, at our
single institution, CHBH, the percentage of seropositivity
has been greater than 50% (unpublished personal data) and
the number of patients over the years has been gradually
increasing (doubled compared to an earlier series in the late
1980’s and early 1990’s) [13]. In the last 2 years (July 2008
to June 2010), a total of 43 consecutive adult black patients
with HL were diagnosed at this single institution. Of these
patients, 29 were HIV seropositive (67%) and 14 (33%)
were seronegative. The clinical characteristics of this retro-
spective review of the seropositive patients are depicted in
Table 1.
3. Pathogenesis
HL is characterized by an admixture of a minority of
neoplastic Reed-Sternberg (RS) cells and a reactive, mixed
inﬂammatory inﬁltrate of lymphocytes, plasma cells, eosin-
ophils, and histiocytes. Cytokines and chemokines are pro-
duced by either the RS cells or the reactive cells. The cytokine
production may explain the presence and maintenance
of an impaired immune response, while the chemokines
(cytokines with chemoattractant properties) play a role in
leucocyte traﬃcking, attract chemokine receptor CCR4-
expressing Th-2 cells and T regulatory cells, and allow a
favourable environment for survival of RS cells [14–16].
Cross-talkbetweentheRScellsandreactivecellsmediatedby
cytokines such as IL-13, IL-17, IL-10, transforming growth
factor beta, and chemokines,principally CCL17 (thymus-
and activation-regulated chemokine, TARC) and CCL22
(macrophage-derived chemokine, MDC), leads to an envi-
ronment where RS cells are able to proliferate, escape from
apoptosis, and survive host antitumour defense [14–16].
The CD4+ T cells surrounding the neoplastic cells in HL
are CD45RO+/CD45RA-/CD45RBdim, suggesting a memory
Th2 phenotype [17].
HIV-associated immunosuppression is a state that per-
mits the unchecked and uncontrolled proliferation of
Epstein-Barrvirus(EBV)infection.EBVhasbeenimplicated
in the aetiopathogenesis of classic HL. EBV-transforming
proteins, such as latent membrane protein-1 (LMP-1), is
expressed in virtually all HIV-HL patients [18–20]. The
expression of EBV-LMP-1 is important in the pathogenesis
of HIV-HL. LMP-1 expression by EBV-infected RS cells
represents the principal mechanism for constitutive nuclear
factor NFκB activity, which confers an apoptosis-resistant
phenotype to the RS cells [19, 20]. EBV-immortalized B cells
also produce CCL17 and CCL22 through LMP-1-mediated
activation of NFκB[ 21].
RS cells represent transformed B cells (postgerminal
center B cells) that originate from preapoptotic germinal
center B cells. They express LMP-1 and display a BCL6-/
CD138+/MUM1/IRF4+ (Interferon Regulatory Factor-4)
phenotype [19, 22, 23]. In addition, LMP2A and EBNA-1
may also contribute to the development of the RS cells,
and they are expressed in the RS cells of this tumour
[18, 20]. LMP2A may promote the survival of the “crippled”
germinal center B cells, thereby aiding in their development
[24].
4. ClinicalPresentationandManagement
HIV-seropositive patients with HL generally pursue a more
aggressive clinical course than seronegative patients. The
behaviour of the disease is diﬀerent, and based on a number
of studies [5, 6, 25–32], the following parameters were
noted: more advanced-stage disease (III and IV), 74–92%,
morefrequentsystemicBsymptoms,70–96%,morefrequent
involvement of extranodal sites, 17–62%, with bone mar-
row involvement being the most common extranodal site,
40–59%, followed by involvement of the liver, 17–40%, and
spleen, 20–30%. Most of the patients (>80%) were males.Advances in Hematology 3
Table 1: Characteristics of patients (n = 29) with HIV-associated Hodgkin’s lymphoma seen at the Chris Hani Baragwanath Hospital (July
2008 to June 2010).
Patient characteristics Number %
Median age (range)—38 years (21–64) mean age—37 years (21–64)
Gender
Male 15 52
Female 14 48
Male:female ratio 1.1:1
ECOG performance status
0–2 18 62
3-4 11 38
“B” symptoms 27 93
Bone marrow involvement
Yes 10 (26) 38
No 16 (26) 62
Unknown 31 1
Stage of lymphoma
I-II 5 (28) 18
III-IV 23 (28) 82
Unclear 14
Histology
Mixed cellularity 13 (24) 54
Nodular sclerosis 8 (24) 33
Lymphocyte depleted 2 (24) 8
Lymphocyte rich 1 (24) 4
Unclassiﬁable/unknown 5 17
CD4 count in μl (range in μl)—mean CD4 = 176 (10–407)
>200/μl 11 (28) 39
<200/μl 17 (28) 61
<100/μl 93 1
<50/μl 62 1
Unknown 13
Risk factor for hiv infection
Heterosexual relation 29 100
Other (intravenous drug use, homosexual relation) 0
Duration of hiv
>1 Year 11 38
<1 Year 18 62
Use of antiretroviral therapy at diagnosis
Yes 13 45
No 16 55
True extranodal involvement (excluding liver, spleen, and bone marrow) 5 17
Liver involvement 13 45
Splenic involvement 8 28
Tuberculosis 17 59
Active disease 11 38
Past infection 62 1
Outcome
Alive 15 52
Dead 11 38
Ltfu (lost to follow up) 3 104 Advances in Hematology
Table 2: Salient diﬀerences between HIV-HL in South Africa and other reported series.
South Africa (Chris Hani Baragwanath
Hospital—CHBH) Other reported series
Gender M:F ratio,1.1:1 Majority male (>80%)
Median CD4 count 176/μl 240–306/μl( I nd i ﬀerent series)
Risk factors Heterosexual relationship Intravenous drug use and homosexual relationship
Diagnosis and duration of
HIV
New diagnosis of HIV, 41% Majority-established or long-standing HIV
Duration of HIV <1 Year, 62%
ARV’s at diagnosis 45% on ARV’S 71–80% on ARV’S
55% ARV naive
Tuberculosis 38% Active disease, 21% past, documented
disease Unknown (low prevalence)
Prognosis and overall
survival Generally unfavourable Less favourable than HIV negative HL. Improving with
standard chemotherapy and concomitant HAART
The median age at presentation was approximately 34 years.
ThemedianCD4countwasmostlyintheintermediaterange
of 240–306/μL[ 5, 6, 25–32]. Compared to HIV-negative HL,
where nodular sclerosis is the dominant histological subtype,
mixed cellularity is most commonly encountered in HIV-
HL, 33–53% [5, 13, 30–32]. Nodular sclerosis is the second
most common histological subtype in HIV-HL, 24–31%.
However, with more severe immunosuppression, nodular
sclerosis becomes infrequent [33]. There is also an increasing
number of patients with lymphocyte-depleted histology, 14–
20%, in HIV-HL [5, 30–32].
Based on the Italian Cooperative Group on AIDS and
Tumors (GICAT), in comparison with patients who were
HAART naive, patients receiving HAART before the onset of
HL are older, have less B symptoms, have higher leukocyte
and neutrophil counts, and have a higher haemoglobin level
[30].
The characteristics of the patients with HIV-associated
HL seen at CHBH over a 2-year period are depicted in
Table 1. There are some striking similarities and diﬀerences
when comparing this cohort with other published studies
outside of Africa. The median age at presentation is similar.
There is no striking male predominance in our patients.
Conversely, the male to female ratio is almost equal at
1.1:1. None of our patients have homosexual contacts or
are intravenous drug users. This is diﬀerent from other
series where homosexuality and intravenous drug use are
signiﬁcant, documented risk groups [1, 2, 5, 6, 30, 31]. The
presentationwithadvanced-stagedisease,morefrequentsys-
temicBsymptoms,morefrequentinvolvementofextranodal
sites, and the histological patterns of disease is similar to
that reported in the literature (see above). The median CD4
count of 176/μL is generally lower in our patients, although
thereareseriesreportedofHIV-HLwithmedianCD4counts
of <200/μL[ 31]. In our series, 12/29 (41%) of the patients
had newly diagnosed HIV at the time of the diagnosis of
HL. In 62% of the patients, the duration of the diagnosis of
HIV (including new patients) was <1 year. Only 45% of the
patients were on antiretroviral therapy at diagnosis of HL,
compared to 71–80% in other series [5, 30, 31]. A further
striking diﬀerence is the high proportion of patients with
Tuberculosis in our series,59% (38% with active disease and
21% with past, documented disease). The high prevalence
of tuberculosis may be a reﬂection of the more severe
immunosuppression in our patients, the delay in diagnosis
of HIV, and hence the absence of antiretroviral therapy use
at diagnosis, and the common occurrence of tuberculosis in
the general population. The presence of tuberculosis, often
in a disseminated fashion, impacts adversely on the clinical
outcome of our patients.
The salient diﬀerences between HIV-HL in South Africa
and other reported series outside of Africa (mostly from
Europe and the USA) [5, 6, 25–32] are detailed in Table 2
above.
The management of HIV-HL is challenging because of
the frequency of infections, likelihood of organ dysfunction
d u et oH I V ,m o r ef r e q u e n ti n v o l v e m e n to ft h eb o n em a r r o w ,
increased myelosuppression, potential interactions of the
antiretrovirals and anti-infectives with chemotherapy, the
advanced and widespread nature of the disease at pre-
sentation, and the preponderance of less favourable his-
tological subtypes. Treatment approaches include vigorous
supportive care (HAART, antivirals, antifungals, neutrophil-
stimulating growth factors), together with standard multia-
gent chemotherapy.
Chemotherapy regimens for HIV-HL such as ABVD,
EBVP, BEACOPP, MOPP/ABV hybrid, and Stanford V are
feasible and can be delivered with concomitant HAART.
The AIDS Clinical Trials Group (ACTG) treated 21 patients
with ABVD for 4–6 cycles and primary use of G-CSF.
Antiretroviral therapy was not used. The complete remission
rate, on intent-to-treat analysis was 43% with an overall
objective response rate of 62%. Median survival for all
patients was 18 months [34]. In a more recent Spanish study,
62 patients with HIV-HL received the standard, full-dose
ABVD and HAART. 87% achieved a complete remission.
The 5-year overall survival (OS) and event-free survival
(EFS) probabilities were 76 and 71%, respectively. The
immunological response to HAART had a positive impact
on OS (P = .002) and EFS (P = .001) [35]. The use of
HAART substantially improves the overall survival in HIV-
associated HL. This is due to a decrease in the incidenceAdvances in Hematology 5
of opportunistic infections, the ability to deliver more
appropriate and aggressive chemotherapy on schedule, and
to the less aggressive presentation of lymphoma in patients
on HAART, in comparison with those lymphomas that arise
in patients who never received HAART [6, 25–27, 29]. In the
study by Hentrich et al., in 2006, 34/59 patients receiving
HAART (n = 34) had a signiﬁcantly better 2-year overall
survival than those not receiving HAART (74% versus 30%,
P<. 001) [36]. The advent of HAART also allows for
more aggressive treatment options such as VEBEP [37],
BEACOPP [38], and Stanford V [39] and the use of high-
dose chemotherapy and autologous stem cell transplantation
(ASCT) in selected patients [40, 41]. However, in general,
response rates and cure rates are lower than in HIV-
seronegative patients, despite the substantial progress made
in the last decade. The challenge at present is to optimise
the use of standard approaches as used in HIV-negative
HL. Once this is established, evaluation of experimental and
newer therapies should follow.
5. Conclusion
HIV is associated with an increased risk of HL. Although
the risk is much less than with NHL, the risk appears to be
increasingwithtime,withHLnowbeingregardedamongthe
most common NADCs. The increased incidence cannot be
explained by more intensive surveillance or diagnostic errors
[42]. The association, which was being largely coincidental
(overlapping and similar age group for both HL and HIV)
may now be increasingly causal, with the most plausible
explanation being attributed to the pathogenetic role of
Epstein-Barr virus infection. Therapy of HIV-associated
HL entails using the same therapeutic approaches as in
seronegativeHL,includingstandardchemotherapyregimens
such as ABVD, and in the salvage setting, autologous stem
cell transplantation in selected patients. In general, the prog-
nosis and overall survival are poorer in HIV-HL compared
to HIV-negative HL. Importantly, the concomitant use of
antiretroviral agents and prophylaxis against certain oppor-
tunistic infections such as Pneumocystis jiroveci pneumonia,
as well as the liberal use of growth factors (granulocyte
colony stimulating factor) and other supportive measures,
constitutes an important aspect of supportive therapy and
has contributed to an improvement in prognosis. The
early recognition and treatment of tuberculosis cannot be
overemphasized in settings where tuberculosis is endemic.
Newer speciﬁc treatment approaches for HL may become
necessary to improve survival, as the association with HIV
increases and becomes clearer in the future. For the present,
HIV-associated HL remains an ongoing challenge.
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